TCR Generierung & Optimierung

Verbesserung der Technologien zur Herstellung hochaffiner natürlicher TCRs mit erhöhter Empfindlichkeit und Sicherheit. Die Allo-Priming-Technologie liefert stärkere und nachhaltigere Immunantworten von TCRs, ohne dass eine Affinitätsreifung erforderlich ist. Standardisierungswerkzeuge wie JOVI Tag ermöglichen die Anreicherung von rekombinanten TCR (rTCR) -exprimierenden T-Zellen, um die Auswahl sicherer TCRs zu erleichtern.

TCR Generierung & Optimierung Publikationen

Dolores J. Schendel. Front. Oncol. 2023, Volume 13 - 2023 | https://doi.org/10.3389/fonc.2023.1216829
Kathrin Davari, Tristan Holland, Laura Prassmayer, Giulia Longinotti, Kenneth P Ganley, Lisa J Pechilis, Iulia Diaconu, Prashant R Nambiar, Michael S Magee, Dolores J Schendel, Daniel Sommermeyer, Christian Ellinger. Journal for ImmunoTherapy of Cancer; 9(3); 25 March 2021; doi: 10.1136/jitc-2020-002035
Obenaus, M., Leitão, C., Leisegang, M., Chen, X., Gavvovidis, I., van der Bruggen, P., Uckert, W., Schendel, D.J. and Blankenstein, T. 2015. Nature Biotechnology 33, 402–407 (2015).
Pinto, S., Sommermeyer, D., Michel, C., Wilde, S., Schendel, D, Uckert, W., Blankenstein T., Kyewski, B. 2014. Eur J Immunol. 2014 May 20 [Epub ahead of print].
Schendel, D.J. and Frankenberger, B. 2013. Oncoimmunology. 2013 Jan 1; 2(1):e22410.
Wilde, S., Geiger, C., Milosevic, S., Mosetter, B., Eichenlaub, S. and D.J. Schendel. 2012. Oncoimmunology. 1(2): 129-140.
Wilde, S., Sommermeyer, D., Leisegang, M., Frankenberger, B., Mosetter, B., Uckert, W. and D. J. Schendel. 2012. J Immunol. 189(2): 598-605.
Wilde, S. and D.J., Schendel. 2012. Oncoimmunology. 1(9):1643-1644.
Wilde, S., Sommermeyer, D., Frankenberger, B., Schiemann, M., Milosevic, S., Spranger, S., Pohla, H., Uckert, W., Busch, D.H. and D.J. Schendel. 2009. Blood 114(10): 2131-2139.

TCR Generierung Abstracts

AACR

TCR-gated control of costimulatory switch protein (CSP) activation in rTCR-T cells expressing PD1-41BB
Maja Buerdek, Petra U. Prinz, Kathrin Mutze, Andrea Coluccio Stefanie Tippmer, Miriam Bosch, Giulia Longinotti, Mario Catarinella, Kathrin Davari, Christiane Geiger, Barbara Loesch, Kirsty Crame, Dolores J. Schendel

Poster

ELRIG-Forum

Evolution by Innovation: Connecting the Dots for TCR-T Therapies
Barbara Lösch

Präsentation

CAR-TCR Summit Europe

Developing Effective Methods to Monitor, Track & Assess T-Cell Efficacy In Vivo & In Vitro
Dolores J Schendel

Präsentation

SITC

A novel library of optimal affinity KRAS mutation-specific T cell receptors associated with multiple HLAs, in combination with a PD1-41BB armoring and enhancement costimulatory switch receptor
Dolores J Schendel, Giulia Longinotti, Mario Catarinella, Melanie Salvermoser, Julia Bittmann, Kirsty Crame, Kathrin Davari and Selwyn Ho

Poster

ESMO

Mitigation of Tumor Microenvironment-Mediated Immunosuppression Using a PD1-41BB Switch Protein with Optimal Affinity TCRs for First-In-Class, 3rd Generation TCR-T Therapies
Kirsty Crame, Giulia Longinotti, Mario Catarinella, Petra U Prinz, Stefanie Tippmer, Kathrin Mutze, Andrea Coluccio, Melanie Salvermoser, Julia Bittmann, Maja Buerdek, Barbara Loesch, Christiane Geiger, Kathrin Davari, and Dolores J Schendel

Poster

CAR-TCR Summit Boston

Improving TCR-T Therapeutic Persistence and Efficacy with Switch Receptors; Dolores Schendel

Präsentation

Immuno-Oncology Summit Europe

PD1-41BB Switch Receptor Technology Added to TCR-Ts Further Enhances Antitumor Activity in vitro and in vivo compared to TCR alone Barbara Lösch

Präsentation

 

AACR

T cells co-expressing a highly potent NY-ESO-1-specific TCR and a chimeric PD1-41BB co-stimulatory switch receptor show a favorable polyfunctional profile for the treatment of solid tumors Andrea Coluccio, Stefanie Tippmer, Kathrin Mutze, Petra U Prinz, Maja Buerdek, Barbara Loesch, Kathrin Davari, Giulia Longinotti, Dolores J Schendel

Poster

CAR-TCR Summit

Combined Molecular & Cellular Tools are Required to Assess Safety of TCR-T Immunotherapies; Tristan Holland

Präsentation

SITC Annual Meeting 2020

Development of a CD8 co-receptor independent T cell receptor specific for tumor-associated antigen MAGE-A4 for next generation T cell-based immunotherapy; Davari K, Holland T, Prassmayer L, Longinotti G, Ganley K, Pechilis LJ, Diaconu I, Nambiar PR, Magee MS, Schendel DJ, Sommermeyer D and Ellinger C

Poster

CIMT – Annual Meeting of the Association for Cancer Immunotherapy 2019, Mainz, Germany

A safe and highly active NY-ESO-1/LAGE-1-specific TCR for adoptive T cell therapy of cancer; Longinotti G, Bürdek M, Weis M, Raffegerst S, Mösch A, Schendel DJ, Wehner C

Poster

AACR- American Association for Cancer Research Annual Meeting 2019, Atlanta

In vitro evaluation of TCR efficacy and toxicity using 3D spheroid models; Maja Buerdek, Kathrin Mutze, Kai Pinkernell, Dolores J. Schendel. Medigene Immunotherapies GmbH, Martinsried, Germany

Abstract

Poster

AACR – American Association for Cancer Research Annual Meeting 2017, Washington, D.C., USA

WT1 and PRAME mRNA transfected TLR 7/8-polarized fast DC vaccines in AML patients mount specific immune responses and impact progression free survival; Iris Bigalke, Guri Solum, Dag Josefsen, Yngvar Fløisand, Kirsti Hønnåshagen, Lisbeth Skoge, Signe Spetalen, Stein Sæbøe-Larssen, Dolores J. Schendel, Gunnar Kvalheim.

Abstract

Isolation and characterization of a PRAME-specific TCR with high avidity, potent antitumor efficacy and a favorable preclinical safety profile; Manon Weis, Carina Wehner, Christian Ellinger, Susanne Wilde, Dolores J. Schendel. Medigene Immunotherapies GmbH, Planegg/Martinsried, Germany

Abstract

SITC – Society for Immunotherapy of Cancer Annual Meeting 2014, National Harbor MD, USA

Wehner C., Ellinger C., Raffegerst S., Wilde S., Mosetter B., Weis M., Longinotti G., Sailer N., Schendel D.J., Milošević S. 2014. Generation of tumor antigen specific CD4+ and CD8+ T cells by simultaneous MHC-I and –II epitope presentation in vitro and in vivo. SITC National Harbor, USA.

Download PDF

CIMT – Cancer Immunotherapy Annual Meeting 2013, Mainz

Ellinger C., Wehner C., Wilde S., Schendel D.J., Milošević S. Mai 2013. MHC Class-II Expression Targeting (CrossTAg) for the Generation of Tumor-Antigen-Specific CD4+ T Lymphocytes. CIMT Mainz, Germany.

Download PDF

CIMT – Cancer Immunotherapy Annual Meeting 2013, Mainz

Wehner C., Ellinger C., Raffegerst S., Wilde S., Mosetter B., Schendel D.J., Milošević S., 2013. Isolation of antigen-specific CD8+ T lymphocytes and molecular characterization of antigenic epitopes. CIMT Mainz, Germany.

Download PDF

Cellular Therapie International Symposium 2013, Erlangen  

Wilde S., Mosetter B., Wehner C., Ellinger C., Milosevic S., Frankenberger B., Schendel D. 2013. Isolation of NY-ESO-1-specific T cell receptors restricted by non-HLA-A*02:01 allotypes for TCR gene therapy. Cellular Therapie International Symposium Erlangen, Germany.

Download PDF